Twist Bioscience (NASDAQ: TWST) shares preliminary Q1 fiscal 2026 revenue update

Rhea-AI Filing Summary

Twist Bioscience Corporation furnished an update on its business by announcing preliminary, unaudited revenue results for the first quarter of fiscal 2026, which ended on December 31, 2025. These figures come from an initial internal review and may change once the company completes its full internal control, review and audit procedures.

The company cautions that the final numbers reported in its upcoming unaudited condensed financial statements for this quarter could differ materially from these preliminary estimates, and advises stockholders not to place undue reliance on the early figures. The revenue update was released through a press release titled “Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue,” which is provided as an exhibit and is furnished rather than filed under securities laws.

FALSE000158128000015812802024-11-182024-11-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 12, 2026

Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-38720

46-2058888

(State or other jurisdiction of incorporation)

(Commission File Number)

(I. R. S. Employer Identification No.)

681 Gateway Boulevard

South San Francisco, CA 94080

(Address of principal executive offices, including ZIP code)

(800) 719-0671

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

TWST

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02Results of Operations and Financial Condition.

On January 12, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its preliminary, unaudited revenue results for the first quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company’s revenue expectations included in this Current Report on Form 8-K are preliminary and unaudited and are subject to change based on the completion of ongoing internal control, review and audit procedures. As a result, these amounts may differ materially from the amounts that will be reflected in the Company’s unaudited condensed financial statements for the fiscal quarter ended December 31, 2025. Accordingly, stockholders should not place undue reliance on this preliminary estimate.

The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press release dated January 12, 2026 titled “Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue”
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026			Twist Bioscience Corporation
			/s/ Judy Yan
			Judy Yan
			Assistant General Counsel and Assistant Secretary

FAQ

What did Twist Bioscience (TWST) disclose in this 8-K filing?

Twist Bioscience disclosed that it issued a press release announcing preliminary, unaudited revenue results for its first fiscal quarter ended December 31, 2025.

Which fiscal period do the preliminary results from Twist Bioscience (TWST) cover?

The preliminary revenue results cover Twist Bioscience’s first quarter of fiscal 2026, which ended on December 31, 2025.

How reliable are Twist Bioscience’s preliminary first quarter 2026 revenue figures?

The company states that its preliminary revenue figures are unaudited and subject to change after completion of internal control, review and audit procedures, and they may differ materially from final reported results.

Where can investors find more details on Twist Bioscience’s preliminary revenue results?

More details are included in the press release titled “Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue”, which is furnished as Exhibit 99.1.

Are Twist Bioscience’s preliminary revenue results considered filed with the SEC?

No. The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liabilities or automatically incorporated into other filings unless specifically referenced.

Does this Twist Bioscience 8-K include full financial statements?

No. It provides a press release with preliminary, unaudited revenue information; full unaudited condensed financial statements for the quarter will be provided separately.